Advanced Enzyme Technologies Limited (ADVENZYMES) fell -5% to ₹305.5 on the NSE on 10 Aug 2026, backed by the release of its Q1 FY27 results showing a 2% rise in revenue but a 5% decline in profit after tax (PAT). The stock is now approaching resistance at ₹306, just 0.1% away. In the specialty chemicals sector, ADVENZYMES plays a crucial role in biotech solutions, and today’s move seems to be more company-specific rather than a sector-wide trend.

Technical setup — trendlines & DMA

Currently, ADVENZYMES is trading just below the 6M resistance trendline at ₹305.81, indicating a breakdown from this level. The 6M support trendline stands at ₹281.16, which is 7.97% below today’s price, offering a buffer if further downside occurs. The 50-DMA at ₹341.8 is above the 200-DMA at ₹316.0, signaling a bullish trend, though the stock is currently in recovery mode, trading above the 200-DMA but below the 50-DMA. In terms of its 52W range of ₹251.9–₹419.0, the current price is in the lower third, suggesting there is room for upside given its -27.1% distance from the 52W high.

Fundamentals & business context

With a PE of 21.7 and a profit margin of 22.6%, ADVENZYMES appears reasonably valued, especially considering its revenue CAGR of 11.3% and profit CAGR of 16.9% over the past five years. The market seems to be pricing in stable growth and profitability, though the recent decline in PAT may raise some concerns. Institutional holding at 19.3% indicates a moderate level of confidence from smart money, though not overwhelmingly bullish. There was no new NSE catalyst today beyond the Q1 results.

Algorithmic scorecard

The overall algorithmic scorecard reflects a balanced view of ADVENZYMES, with strong fundamental metrics offsetting weaker technical signals. The excellent efficiency score, driven by a 22.6% profit margin, highlights the company’s ability to maintain strong profits. The very low debt score, with a D/E ratio of 0.03, underscores its excellent financial health. On the technical side, the bearish sentiment score, with more down days than up days in the last 30, and the mixed momentum score, reflecting inconsistent price growth, are areas of concern. These technical weaknesses suggest that while the business fundamentals are solid, the stock’s price action has been volatile and unpredictable.

Company outlook

Management provided a steady business outlook with a focus on optimizing capacity allocation and improving supply chain efficiencies. They anticipate healthy growth from the Indian market across all segments and expect margins to remain stable with possible 1-2% variability. Plans include increasing R&D expenditure by INR 50 million and CapEx by INR 50 crores, with the operationalization of a new R&D center in Nashik in the latter half of FY26. Additionally, there are plans for potential capacity expansion in one of the subsidiary companies by September and a strategic focus on increasing revenue share from existing customers and expanding into new markets.

Get all details on ADVENZYMES — P&L, peers, shareholding and more on TradeAlone.

Advanced Enzyme Technologies Limited (Advanced Enzymes; NSE: ADVENZYMES; BSE: 540025), a leading specialty biotech company, announced their unaudited financial results for the first quarter ended June 2026. The total revenue from operations grew by 2% year-on-year to ₹1,898 million in Q1 FY27 from ₹1,859 million in Q1 FY26. However, the profit after tax (PAT) de-grew by 5% to ₹386 million compared to ₹404 million in the same quarter last year.

Financial Highlights

The consolidated EBITDA during Q1 FY27 stands at ₹510 million as compared to ₹564 million in Q1 FY26, a decrease of 10%. Profit before tax (PBT) stands at ₹535 million during Q1 FY27 as against ₹598 million in Q4 FY26, a decrease of 10%. The EBITDA margin stands at 27%, PBT margin at 28%, and PAT margin at 20% during the quarter.

Segmental Performance

The Human Nutrition segment declined by 7% year-on-year to ₹1,139 million in Q1 FY27, compared with ₹1,221 million in Q1 FY26. The Animal Nutrition segment reported a 3% year-on-year decline to ₹252 million in Q1 FY27, compared with ₹260 million in Q1 FY26. The Bio-Processing segment delivered a strong performance during the quarter, with revenue increasing by 30% year-on-year to ₹306 million in Q1 FY27 from ₹236 million in Q1 FY26.

The Specialized Manufacturing segment contributed 11% to the Company’s total revenue during the quarter, with revenue increasing by 41% year-on-year to ₹200 million. Geographically, domestic sales accounted for ₹937 million in Q1 FY27 as compared to ₹979 million in Q1 FY26, lower by 4%. The total revenue comprises of international sales amounting to ₹961 million in Q1 FY27 as compared to ₹881 million in Q1 FY26, an increase of 9%.

Advanced Enzymes remains committed to enhancing and strengthening its business model by maintaining a strong focus across its three key segments —Human Nutrition, Animal Nutrition, and Bio-Processing.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Advanced Enzyme Technologies Limited

Advanced Enzyme Technologies Limited belongs to the Basic Materials › Specialty Chemicals sector. Here’s a quick read on where the business and the stock stand today.

Advanced falls 9.2% over three months and has not found a floor yet. Premium net margins of 22.6% demonstrate strong cost discipline and a wide competitive moat. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The stock gains 1.8% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Revenue grows at 11.3% and profits at 16.9% CAGR, with D/E of 0.03. Meanwhile, the stock dips 9.2% in three months without any fundamental deterioration. Consequently, the stock quietly becomes cheaper relative to earnings power. For long-term investors, that is a feature. Check Fundamentals of Advanced Enzyme Technologies Limited.

Advanced Enzyme Technologies Limited (ADVENZYMES) breaks out with a +7% gain to ₹338.95 on the NSE today, clearing its 6-month resistance trendline. This move comes on the heels of the company’s Annual General Meeting proceedings and voting results filed with the Exchange, though no specific catalyst was cited. ADVENZYMES operates in the specialty chemicals segment within basic materials, and today’s breakout suggests a company-specific momentum rather than a sector-wide rally.

Technical setup — trendlines & DMA

From a technical standpoint, ADVENZYMES has broken above its 6-month resistance trendline, which ended at ₹305.81, signaling a potential shift in momentum. The stock is now trading 9.78% above this resistance level, with the 6-month support trendline far below at ₹286.82, indicating a significant buffer if pullbacks occur. Despite this breakout, the stock remains 9.32% below its 50-day moving average (DMA) of ₹347.5, suggesting it is not yet overextended. The stock’s position in the middle third of its 52-week range, up 52% from the low and down 19.1% from the high, implies there’s room for further upside without being overbought.

Fundamentals & business context

Fundamentally, ADVENZYMES presents a mixed picture. With a PE of 20.9 and profit margins at 22.6%, the stock is trading at a reasonable valuation considering its revenue CAGR of 11.3% and profit CAGR of 16.9% over the past five years. This suggests the market is pricing in steady growth rather than a turnaround. The 18.6% institutional ownership indicates a cautious but present interest from smart money, though not overwhelmingly bullish. There’s no specific NSE catalyst today, pointing to a technical rather than fundamental driver for the move.

Algorithmic scorecard

The algorithmic scorecard paints a picture of a stock with strong fundamentals but weaker technicals. The standout fundamental strengths are the company’s excellent efficiency, reflected in its 22.6% profit margin, and its very low debt levels, with a D/E ratio of 0.03. These factors suggest a financially healthy company with strong profit-keeping capabilities. On the technical side, the bullish trend indicated by the 50-DMA being above the 200-DMA is a positive sign. However, the stock’s weak position below both moving averages and its bearish sentiment over the last 30 days, with more down days than up, highlight the technical challenges ahead. These mixed signals suggest cautious optimism, with a need to watch for technical confirmation of the breakout.

Company outlook

Management’s outlook for ADVENZYMES remains steady, with a focus on optimizing capacity allocation and improving supply chain efficiencies. They anticipate healthy growth from the Indian market across all segments, with margins expected to remain stable, possibly varying by 1-2%. The company plans to increase R&D expenditure by INR 50 million and CapEx by INR 50 crores, signaling a commitment to innovation and growth. Operationalization of the new R&D center in Nashik and potential capacity expansion in a subsidiary by September are key initiatives. The strategic focus on increasing revenue share from existing customers and expanding into new markets underscores a balanced approach to growth.

Get all details on ADVENZYMES — P&L, peers, shareholding and more on TradeAlone.